About Dallas Biomedical
Developing biopharmaceutical products based on proprietary technologies centered on the vascular system. The company has utilized these technologies to develop cancer diagnostics and therapeutics. Two drugs, an immunosuppressor dipeptide and IMTOX22, are currently in phase I clinical trials. The immunosuppressor dipeptides are used as a bone marrow purging agent to prevent rejection after marrow transplants, especially in donors who are not perfect genetic matches. IMTOX22 is used as an antibody-targeted toxin to selectively destroy B cells in patients with B-cell lymphoma. Two additional therapeutics have shown promising results in preclinical trials. One is a vascular targeting technology to treat malignant tumors by destroying the capillaries supplying nutrients required for tumor growth. The second therapeutic combines antibody targeting and magnetic resonance imaging (MRI) to develop antibody-targeted MRI agents. These antibody-targeted MRI agents are highly sensitive, providing high resolution without radiation.